Skip to main content
Erschienen in: Archives of Dermatological Research 10/2023

04.09.2023 | REVIEW

Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis

verfasst von: Parsa Abdi, Christian Awad, Michelle R. Anthony, Christopher Farkouh, Bret Kenny, Howard I. Maibach, Boluwaji Ogunyemi

Erschienen in: Archives of Dermatological Research | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Androgenetic alopecia is a widespread condition that is the most common type of hair loss affecting approximately 58% and 40% of men and women by the age of 50, respectively. Patients have been known to experience severe distress due to androgenetic alopecia, including anxiety, low self-esteem, and depression. The objective of this study was to conduct a systematic review and meta-analysis to determine the efficacy of combination therapy using topical minoxidil and microneedling compared to topical minoxidil alone. This systematic review of randomized controlled trials was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. The literature search was performed using Scopus, Cochrane, Embase, and the National Institutes of Health’s United States National Library of Medicine from inception through January 20, 2023. Randomized controlled trials examining the efficacy of combinational therapy and monotherapy using microneedling and minoxidil on patients with clinically diagnosed androgenetic alopecia were included after screening titles, abstracts, and full texts. Two independent reviewers selected studies, extracted data, and appraised the risk of bias using the Cochrane risk of bias assessment tool. Ten randomized controlled trials, including 466 patients, were selected for this review and eight studies were ultimately included in the meta-analysis. All eight studies displayed a statistically significant increase in total hair count [standard mean difference (SMD) 1.76; 95% CI 1.26–2.26; P < 0.00001]; however, the evidence did not support a statistically significant increase in hair diameter (SMD 0.82; 95% CI − 0.01 to 1.65; P = 0.05). No scarring nor serious adverse events were reported in any of the studies. The findings of this meta-analysis strongly support the utilization of a multimodal therapeutic approach of minoxidil and microneedling for hair growth in patients with androgenetic alopecia. However, variations in factors such as rating scale measurements, microneedling methods, and areas of treatment may have resulted in confounding. Further randomized controlled, large-sample trials employing rigorous methodologies are needed to gain a more comprehensive understanding regarding treatment efficacy, namely the impact of combinational therapy on hair diameter.
Clinical trial registrations This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42023391164) and the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) database (INPLASY202310031).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
13.
Zurück zum Zitat Liang X, Chang Y, Wu H et al (2022) Efficacy and safety of 5% minoxidil alone, minoxidil plus oral spironolactone, and minoxidil plus microneedling on female pattern hair loss: a prospective, single-center, parallel-group, evaluator blinded, randomized trial. Front Med 9:905140. https://doi.org/10.3389/fmed.2022.905140CrossRef Liang X, Chang Y, Wu H et al (2022) Efficacy and safety of 5% minoxidil alone, minoxidil plus oral spironolactone, and minoxidil plus microneedling on female pattern hair loss: a prospective, single-center, parallel-group, evaluator blinded, randomized trial. Front Med 9:905140. https://​doi.​org/​10.​3389/​fmed.​2022.​905140CrossRef
20.
Zurück zum Zitat Bao L, Zong H, Fang S, Zheng L, Li Y (2022) Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. J Dermatol Treat 33(1):483–493. https://doi.org/10.1080/09546634.2020.1770162CrossRef Bao L, Zong H, Fang S, Zheng L, Li Y (2022) Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. J Dermatol Treat 33(1):483–493. https://​doi.​org/​10.​1080/​09546634.​2020.​1770162CrossRef
24.
Zurück zum Zitat Ro BI, Son HO, Chun SW, Shin HC (2016) Therapeutic effects of growth factor cocktail treatment in patients with androgenetic alopecia according to the depth of microneedle. Korean J Dermatol 54(3):184–189 Ro BI, Son HO, Chun SW, Shin HC (2016) Therapeutic effects of growth factor cocktail treatment in patients with androgenetic alopecia according to the depth of microneedle. Korean J Dermatol 54(3):184–189
31.
Zurück zum Zitat Goldust M (2020) Minoxidil 15% solution versus minoxidil 5% solution in the treatment of androgenetic alopecia. Br J Dermatol 183(Suppl):91 (abstract BH107) Goldust M (2020) Minoxidil 15% solution versus minoxidil 5% solution in the treatment of androgenetic alopecia. Br J Dermatol 183(Suppl):91 (abstract BH107)
32.
Zurück zum Zitat McCoy J, Goren A, Kovacevic M, Shapiro J (2016) Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 30(4):1153–1155PubMed McCoy J, Goren A, Kovacevic M, Shapiro J (2016) Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 30(4):1153–1155PubMed
33.
Metadaten
Titel
Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis
verfasst von
Parsa Abdi
Christian Awad
Michelle R. Anthony
Christopher Farkouh
Bret Kenny
Howard I. Maibach
Boluwaji Ogunyemi
Publikationsdatum
04.09.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 10/2023
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-023-02688-1

Weitere Artikel der Ausgabe 10/2023

Archives of Dermatological Research 10/2023 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.